Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, 52-week, Randomized, Active-Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Next Previous
Search
Trial Profile

A Phase 3, 52-week, Randomized, Active-Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Revefenacin (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational
  • Sponsors Mylan

    • Most Recent Events

    • 19 May 2021 Results of subgroup analyses (n=812) assessing the efficacy and safety of revefenacin in improving lung function in women versus men with moderate to very severe chronic obstructive pulmonary disease from Study 0126 (NCT02459080), 0127 (NCT02512510) and Study 0128 (NCT02518139) trials, presented at the 117th International Conference of the American Thoracic Society.
    • 20 May 2019 Results from a a subgroup analysis of data from two 12-week replicate placebo-controlled trials (n=812)and a 52-week randomized, tiotropium-controlled safety trial were presented in a Theravance Biopharma Media Release.
    • 20 May 2019 According to a Theravance Biopharma media release, results from a a subgroup analysis of data from two 12-week replicate placebo-controlled trials (n=812)and a 52-week randomized, tiotropium-controlled safety trial were presented at the 2019 ATS International Conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top